文献速递头颈与中枢神经肿瘤

头颈癌患者对HPV16 E6和E7蛋白的免疫反应与患者结局

Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究基于马萨诸塞州大波士顿地区1054例头颈癌患者,发现HPV16 E6/E7血清阳性与总生存改善相关(HR 0.33),且在各解剖部位及不同烟酒暴露组中关联相似;在162例同时有血清学和p16免疫组化数据的患者中,口咽癌两种指标与生存关联相似,但全头颈癌仅血清学与结局相关。

要点

  • HPV16 E6/E7血清阳性与头颈癌总生存改善相关(HR 0.33,95%CI 0.24-0.45,P<.001)。
  • 血清阳性与口咽、口腔、喉癌生存改善均相关,不同烟酒暴露组关联相似。
  • 口咽癌中血清学与p16 IHC与生存关联相似,全头颈癌仅血清学与结局相关。

核心结论

  • 对HPV16癌蛋白的阳性血清学反应可能是评估HPV相关疾病临床结局的最佳方法,因其与所有类型疾病的生存相关且不依赖病理材料。

研究设计与样本

  • 研究为基于人群的研究,纳入马萨诸塞州大波士顿地区1999-2003年和2006-2011年的1054例头颈癌患者。
  • 主要结局为与HPV16 E6和E7血清阳性相关的全因生存。

主要发现

  • 1054例患者反映该时间段治疗人群的人口学特征(75%男性;平均年龄59岁)。
  • 血清阳性与总生存改善非常强相关(HR 0.33;95%CI 0.24-0.45;P<.001),无证据表明由滴度水平评估的免疫反应强度影响结局。
  • 血清阳性与所有头颈癌部位的生存改善相关:口咽癌HR 0.26(95%CI 0.18-0.39);口腔癌HR 0.45(95%CI 0.18-0.80);喉癌HR 0.29(95%CI 0.10-0.85)。
  • 血清阳性关联在吸烟和/或饮酒暴露组间相似:低暴露HR 0.52(95%CI 0.20-1.36);中暴露HR 0.42(95%CI 0.25-0.70);重暴露HR 0.51(95%CI 0.36-0.73)。
  • 在162例同时有HPV血清学和p16免疫组化检测的患者亚组中,口咽癌两种检测与生存关联相似(血清学HR 0.16,95%CI 0.03-0.47;p16 HR 0.16,95%CI 0.03-0.46),而考虑所有头颈癌病例时仅血清学与结局相关(血清学HR 0.49,95%CI 0.23-1.04;p16 HR 0.65,95%CI 0.30-1.42)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathology-based measures of human papillomavirus (HPV) status are routinely obtained in the care of head and neck cancer and are clearly associated with patient outcome for cancers of the oropharynx. However, it is unclear if HPV status is of high value for cancers of the larynx and oral cavity. In addition, it is possible to assess HPV infection using serology-based methods; however, the suitability of this pathology-independent measure for predicting patient outcome in head and neck cancer is unknown. OBJECTIVE: To investigate whether immunologic response to HPV16 is associated with patient survival across anatomic sites, independent of smoking and drinking history. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusetts, area (1999-2003, 2006-2011). MAIN OUTCOMES AND MEASURES: All-cause survival in relation to HPV16 E6 and E7 seropositivity. RESULTS: The 1054 patients reflected the demographics of those treated in this timeframe (75% male; mean age, 59 years). Seropositivity was very strongly associated with improved survival overall (hazard ratio HR], 0.33; 95% CI, 0.24-0.45; P < .001), with no evidence that the magnitude of immune response, as assessed by titer levels, effected outcome. Seropositivity was associated with improved patient survival across all head and neck cancer sites: HR for oropharynx cancer, 0.26; 95% CI, 0.18-0.39; for oral cavity cancer, 0.45; 95% CI, 0.18-0.80; and for larynx cancer, 0.29; 95% CI, 0.10-0.85. In addition, the associations with seropositivity were similar across smoking and/or drinking exposure groups: HRfor low exposure, 0.52; 95% CI, 0.20-1.36; for moderate exposure, 0.42; 95% CI, 0.25-0.70; for heavy exposure, 0.51; 95% CI, 0.36-0.73. In a subset of 162 patients with both HPV serology and p16 immunohistochemical (IHC) measures available, both measures were similarly associated with survival in the oropharynx (HR for serology, 0.16; 95% CI, 0.03-0.47; for p16 measures, 0.16; 95% CI, 0.03-0.46), whereas only serology was associated with outcome when considering all head and neck cancer cases (HR for serology,0.49; 95% CI, 0.23-1.04; for p16, 0.65; 95% CI, 0.30-1.42). CONCLUSIONS AND RELEVANCE: Collectively, these data suggest that a positive serologic response to HPV16 oncoproteins may be the best approach to assess HPV-disease for clinical outcome because it is associated with survival for all types of disease and is a marker that is not dependent on pathology material.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nelson HH, Pawlita M, Michaud DS, et al. Immune Response to HPV16 E6 and E7 Proteins and Patient Outcomes in Head and Neck Cancer. JAMA Oncol. 2017. PMID: 27930753. doi:10.1001/jamaoncol.2016.4500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。